About Ascendis Pharma A/S
https://ascendispharma.comAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
CEO
Jan Moller Mikkelsen
Compensation Summary
(Year )
ETFs Holding This Stock
IBB
Weight:0.83%
Shares:345.44K
CGGR
Weight:0.23%
Shares:214.14K
XWEH.DE
Weight:0.36%
Shares:189.39K
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.28M
Value:$2.23B
WESTFIELD CAPITAL MANAGEMENT CO LP
Shares:5.26M
Value:$1.14B
AVORO CAPITAL ADVISORS LLC
Shares:5.11M
Value:$1.11B
Summary
Showing Top 3 of 320
About Ascendis Pharma A/S
https://ascendispharma.comAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $213.63M ▲ | $180.28M ▲ | $-60.99M ▼ | -28.55% ▼ | $-1 ▼ | $-53.35M ▼ |
| Q2-2025 | $158.04M ▲ | $179.55M ▼ | $-38.85M ▲ | -24.58% ▲ | $-0.64 ▲ | $2.32M ▲ |
| Q1-2025 | $100.95M ▼ | $187.65M ▲ | $-94.63M ▼ | -93.73% ▼ | $-1.58 ▼ | $-44.23M ▼ |
| Q4-2024 | $173.92M ▲ | $159.51M ▲ | $-38.47M ▲ | -22.12% ▲ | $-0.64 ▲ | $-37.89M ▲ |
| Q3-2024 | $57.83M | $143.38M | $-99.2M | -171.52% | $-1.69 | $-71.13M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $539.09M ▲ | $1.15B ▲ | $1.33B ▲ | $-174.07M ▲ |
| Q2-2025 | $494.05M ▼ | $1.09B ▲ | $1.28B ▲ | $-187.57M ▲ |
| Q1-2025 | $517.92M ▼ | $1.06B ▼ | $1.25B ▼ | $-189.81M ▼ |
| Q4-2024 | $559.54M ▼ | $1.18B ▲ | $1.29B ▲ | $-105.71M ▼ |
| Q3-2024 | $625.51M | $1.09B | $1.19B | $-97.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-60.99M ▼ | $2.15M ▲ | $-53K ▲ | $38.85M ▲ | $45.05M ▲ | $2.1M ▲ |
| Q2-2025 | $-38.86M ▲ | $-7.34M ▲ | $-4.34M ▼ | $6.98M ▲ | $-23.88M ▲ | $-11.68M ▲ |
| Q1-2025 | $-94.63M ▼ | $-14.31M ▲ | $-703K ▼ | $-18.02M ▼ | $-41.62M ▲ | $-15.02M ▲ |
| Q4-2024 | $-38.47M ▲ | $-87.18M ▼ | $-384K ▲ | $87K ▼ | $-65.97M ▼ | $-87.56M ▼ |
| Q3-2024 | $-99.2M | $-56.13M | $-503K | $427.87M | $366.82M | $-56.6M |
Revenue by Geography
| Region | Q3-2022 | Q4-2022 | Q4-2023 | Q1-2023 |
|---|---|---|---|---|
 CHINA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Europe | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 North America | $-10.00M ▲ | $50.00M ▲ | $160.00M ▲ | $30.00M ▼ |
CEO
Jan Moller Mikkelsen
Compensation Summary
(Year )
ETFs Holding This Stock
IBB
Weight:0.83%
Shares:345.44K
CGGR
Weight:0.23%
Shares:214.14K
XWEH.DE
Weight:0.36%
Shares:189.39K
Summary
Showing Top 3 of 48
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.28M
Value:$2.23B
WESTFIELD CAPITAL MANAGEMENT CO LP
Shares:5.26M
Value:$1.14B
AVORO CAPITAL ADVISORS LLC
Shares:5.11M
Value:$1.11B
Summary
Showing Top 3 of 320